News
Inhibikase (IKT) pivots to IkT-001Pro for PAH amid competition like Merck’s sotatercept. Backed by $97.5M, results will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback